• Home
  • NEW DAY MEDICINE
  • 12 (74) 2024
  • 160 - 12 (74) 2024 - Kholikov A.Yu. - “PREVALENCE OF DIABETIC NEPHROPATHY STAGE 1-3 IN THE REPUBLIC OF UZBEKISTAN DYNAMICS FROM 2016 TO 2023”

160 - 12 (74) 2024 - Kholikov A.Yu. - “PREVALENCE OF DIABETIC NEPHROPATHY STAGE 1-3 IN THE REPUBLIC OF UZBEKISTAN DYNAMICS FROM 2016 TO 2023”

“PREVALENCE OF DIABETIC NEPHROPATHY STAGE 1-3 IN THE REPUBLIC OF UZBEKISTAN DYNAMICS FROM 2016 TO 2023”

Kholikov A.Yu. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

The purpose of the study is to study the prevalence of diabetic nephropathy in the Republic of Uzbekistan for the period from 2016 to 2023. Material and research methods. The study was conducted on the basis of the Republican Specialized Scientific and Practical Medical Center of Endocrinology of the Ministry of Health of the Republic of Uzbekistan, Tashkent. The study included 22,319 people with type 2 diabetes from 13 regions of the Republic of Uzbekistan and Tashkent, who were divided into 3 groups: Research results. The largest number of patients with stage 1-3 DN in 2016 there were 3533 patients in Tashkent and in Samarkand region - 2175 patients, the number of which increased to 5469 in 2023 and 3012 patients, respectively. Total for the period from 2016 to 2023 the number of patients with DN increased from 14,148 to 24,964, that is, by 10,816 persons. If in 2016 the number of deaths from chronic renal failure with type 2 diabetes in the Republic of Uzbekistan was 703 cases, then in 2023 it reached 1330 people, that is, it increased by 2 times. At the same time, in the Fergana region the number of deaths in 2016 was the highest - 123 cases, and in 2023, also in this region, this number remained maximum - 289 patients (21.7%). Conclusions. The prevalence of diabetic nephropathy stages 1-3 in dynamics from 2016 to 2023 increased significantly.

Key words: prevalence, diabetic nephropathy, mortality

First page

842

Last page

847

For citation:Kholikov A.Yu. - “PREVALENCE OF DIABETIC NEPHROPATHY STAGE 1-3 IN THE REPUBLIC OF UZBEKISTAN DYNAMICS FROM 2016 TO 2023”//New Day in Medicine 12(74)2024 842-847 https://https://newdayworldmedicine.com/en/new_day_medicine/12-74-2024

List of References

  1. M Brijesh, P Saurav. Comparative study of significance of serum cystatin-C, serum creatinine and microalbuminuria estimation in patients of early diabetic nephropathy //J Diabetes Metab 2015.
  2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. //Diabetes Res Clin Pract 2010;87:4-14.
  3. Balaji R., Duraisamy R., Kumar M. P. Complications of diabetes mellitus: A review //Drug Invention Today. 2019;12:1.
  4. Beckman JA, Creager MA. Vascular Complications of Diabetes. //Circ Res. 2016 May 27;118(11):1771-85. doi: 10.1161/CIRCRESAHA.115.306884.
  5. Long A. N., Dagogo‐Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection //The journal of clinical hypertension. 2011;13(4):244-251.
  6. Maggiore U. et al. Long-term risks of kidney living donation: review and position paper by the ERA-EDTA DESCARTES working group //Nephrology Dialysis Transplantation. 2017;32(2):216-223.
  7. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. //Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045. doi: 10.2215/CJN.11491116.
  8. Selby NM, Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. //Diabetes Obes Metab. 2020 Apr;22 Suppl 1:3-15. doi: 10.1111/dom.14007
  9. Sternlicht H, Bakris GL. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? //Blood Purif. 2016;41(1-3):139-43. doi: 10.1159/000441264
  10. Liu R, Li G, Cui XF, Zhang DL, Yang QH, Mu XY, Pan WJ. Methodological evaluation and comparison of five urinary albumin measurements. //J Clin Lab Anal. 2011;25(5):324-9. doi: 10.1002/jcla.20477
  11. Brenner BM, Hostetter TH, Humes HD. Molecular basis of proteinuria of glomerular origin. //N Engl J Med. 1978 Apr 13;298(15):826-33. doi: 10.1056/NEJM197804132981507
  12. Jim B, Santos J, Spath F, Cijiang He J. Biomarkers of diabetic nephropathy, the present and the future. //Curr Diabetes Rev. 2012 Sep;8(5):317-28. doi: 10.2174/15733991280208//3478.
  13. Bonventre J. V. Current biomarkers in kidney disease: Dawning of a new era //ASN Kidney News. 2014;6:7-8.
  14. Thornton Snider J, Sullivan J, van Eijndhoven E, Hansen MK, Bellosillo N, Neslusan C, O'Brien E, Riley R, Seabury S, Kasiske BL. Lifetime benefits of early detection and treatment of diabetic kidney disease. //PLoS One. 2019 May 31;14(5):e0217487. doi: 10.1371/journal.pone.0217487.
  15. Смирнов А.В., Добронравов В.А., Каюков И.Г. и др. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Национальные рекомендации //Нефрология. 2012;16(1):89-115.
  16. Смирнов А.В., Каюков И.Г., Есаян А.М., Кучер А.Г. и др.. Проблема оценки скорости клубочковой фильтрации в современной нефрологии: новый индикатор – цистатин С // Нефрология 2005;9(3):16-27.
  17. Швецов М.Ю., Бобкова И.Н., Колина И.Б., Камышова Е.С. Современные принципы диагностики и лечения хронической болезни почек: методическое руководство для врачей. Шилов ЕМ, ред. // Саратов. – 2011.

    file

    download